A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia

NCT07283640 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Blinatumomab
Revumenib
Lymphoblastic Leukemia
KMT2A-rearranged

Interventions

DRUG: Revumenib
DRUG: Blinatumomab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]